Vornorexant (ORN-0829; TS-142) is a potent dual OX1R and OX2R antagonist with IC 50 values of 1.05 nM and 1.27 nM, respectively. Vornorexant exhibits potent sleep-promoting effects in vivo and can be used for insomnia treatment research.

Vornorexant (oral administration; 1-10 mg/kg) exhibits potent sleep-promoting effects at a po. dose of 1 mg/kg in a rat polysomnogram study. It results in a dose-dependent increase in the percentage of total sleep[1].Vornorexant exhibits optimal PK properties with a rapid T max and short half-lives in rats and dogs. The T 1/2 is 0.238 hours and 1.16 hours, respectively in rat and dog[1]. Animal Model: Rat[1]Dosage: 1, 3, 10 mg/kg Administration: Oral administration to rats prior to turning the light off (start of the active phase); 1-10 mg/kg Result: Possessed promising sleep-inducing and sleep-promoting effects.

1517965-94-4

C23H22FN7O2

447.474

TS-142;ORN-0829;Vornorexant

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years